Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sits in the top decile of US sponsors by registered trial count (#348 of 15,742 sponsors by registered trial count).
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center: 55 sponsored US clinical trials, 1 recruiting.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sponsors 55 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 46 completed. 16 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is LET, with 1 trials.
Top-decile sponsor footprint
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ranks in the top decile of sponsors by registered trial count (#348 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
46 of 50 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
55 total, page 2 of 2
L-Glutamine Therapy for Sickle Cell Anemia
NCT00586209
Dietary Protein Requirements in Hemodialysis Patients
NCT02194114
Arterial pH and Total Body Nitrogen Balances in APD
NCT00586131
A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
NCT00386958
The Significance of Funguria in Hospitalized Patients
NCT00787085
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 12 |
| Phase 3 | 4 |
| Phase 4 | 12 |
Therapeutic Areas
What is open in the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center pipeline
1 recruiting of 55 indexed (2% open); 46 completed (84%).
Phase mix: 16 late (III/IV) vs 19 early (I/II) (balanced across stages).
Top condition: LET (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center: open-pipeline peers nationwide
Peers matched on 55 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 55 trials (± recruiting share)
- Connecticut Children's Medical Center · 55 trials · 27% recruiting
- Radicle Science · 55 trials · 7% recruiting
- Lexicon Pharmaceuticals · 56 trials · 2% recruiting
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Alcon Research · 2% recruiting · 275 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
- Eisai · 2% recruiting · 287 trials
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
Related
What to do with this Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center page
55 registered trials is a research-attention snapshot, not an endorsement of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center or any single study.
- 1 of Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- LET is the condition Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See LET trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center pipeline card: 55 registered trials from official public datasets.Report a data error.